3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Lung Neoplasms
3
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Medullary
2
Carcinoma, Bronchogenic
2
Carcinoma
2
Adenocarcinoma
2
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Glandular and Epithelial
1
Multiple Endocrine Neoplasia Type 2a
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Digestive System Neoplasms
1
Interventions
pembrolizumab
13
Gemcitabine
9
Cisplatin
7
Cetuximab
7
Psychiatric Rehabilitation
6
Paclitaxel
6
Magnetic Resonance Spectroscopy
6
Fluorouracil
6
Early Intervention, Educational
6
Carboplatin
6
cediranib
5
Leucovorin
5
sargramostim
4
Standard of Care
4
Pemetrexed
4
Oxaliplatin
4
Methods
4
Erlotinib Hydrochloride
4
Docetaxel
4
Cyclophosphamide
4
selpercatinib
3
aldesleukin
3
adagrasib
3
Trastuzumab
3
Therapeutics
3
Nivolumab
3
Irinotecan
3
Fluorodeoxyglucose F18
3
Bortezomib
3
Bevacizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
pralsetinib
×
Thoracic
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA